Recurrent Central Serous Chorioretinopathy Under Combined Vemurafenib and Cobimetinib Treatment.
Klinik Pallas, Olten, Switzerland (Director: Prof. Dr. Heinrich Gerding).
P
P
Kouros
Klinik Pallas, Olten, Switzerland (Director: Prof. Dr. Heinrich Gerding).
H
H
Gerding
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001384:Azetidines / Q000008:administration & dosage / Q000009:adverse effects*; D056833:Central Serous Chorioretinopathy / Q000139:chemically induced* / Q000175:diagnosis* / Q000473:pathology; D004359:Drug Therapy, Combination; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects*; D012008:Recurrence; D012878:Skin Neoplasms / Q000188:drug therapy; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*; D016896:Treatment Outcome; D000077484:Vemurafenib
D000970:Antineoplastic Agents; D001384:Azetidines; D007211:Indoles; D010880:Piperidines; D013449:Sulfonamides; D000077484:Vemurafenib; C574276:cobimetinib